Please select the eligibility criteria that correspond to the clinical trial below.
Title: PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial
Brief Summary: Trial name: PAracetamol and NSAID in combination: A randomised, blinded, parallel, 4-group clinical trial

Trial acronym: PANSAID

Background: Effective postoperative pain management is essential for the well-being and rehabilitation of the surgical patient. No "gold standard" exists after total hip arthroplasty (THA) and combinations of different non-opioid medications are used with virtually no evidence for additional analgesic efficacy compared to monotherapy.

Objectives: The objective of this trial is to investigate the analgesic effects and safety of paracetamol and ibuprofen and their combination in different dosages after THA.

Intervention: Patients are randomised to 4 groups: A) paracetamol 1 g x 4 and ibuprofen 400 mg x 4; B) paracetamol 1 g x 4 and placebo (ibuprofen); C) placebo (paracetamol) and ibuprofen 400 mg x 4; and D) paracetamol 0,5 g x 4 and ibuprofen 200 mg.

Design: Placebo controlled, parallel 4-group, multicentre trial with adequate centralised computer-generated allocation sequence and allocation concealment with varying block size and stratification by site. Blinding of assessor, investigator, caregivers, patients, and statisticians.

Sample size: 556 eligible patients are needed to detect a difference of 10 mg morphine the first postoperative day with a standard deviation of 20 mg and a type 1 error rate of 0,004 (two-sided) and a type 2 error rate of 0,10.


Options:
A: Inclusion Criteria:

* Programmed abdominal or thoracic surgery
* Patients \> 18 yrs
* Patients are aware of German language
* Participation is voluntary
* ASA-risk class 1-2 (American Society of Anesthesiologists guidelines)

Exclusion Criteria:

* Severe cardiac, pulmonary, renal or neurologic disease
* ASA risk III and IV
* Insulin dependent Diabetes mellitus
* Polyneuropathy
* Chronic pain
* Use of analgesic drugs
* Ulcus duodeni
* Ulcus ventriculi
* Time after intestinal bleeding
* Allergy reactions towards coxibes or coxibe-like drugs
* Pregnancy and lactation
* Severe hepatic disease (Albumin \< 25 g/l or Child-Pugh-Score ≥ 10)
* Children and Teenager \< 16 years
* Chronic intestinal inflammation
* Heart failure (NYHA II - IV)
* Inbalancend arterial hypertension
B: Inclusion Criteria:

* Healthy volunteers between 18-28 years old
* Clinical and radiographic diagnosis of impacted mandibular third molars, which the surgical approach may include flap and osteotomy procedures.
* surgery classified as simple to moderate
* Voluntary acceptance of written consent, previously approved by institutional ethics committee

Exclusion Criteria:

* Prior administration of analgesic or anti-inflammatory drugs
* History of drug dependence
* History of allergic reactions to any of the drugs selected, or local anesthetics
* Simultaneous presence of oral pathologies that may interfere with the surgical procedure
C: Inclusion Criteria:

* ASA I-III
* weight (kilos) over 40 kg
* height (centimeters) over 155 cm
* non-anemic
* indication for primary TKA (total knee arthroplasty)

Exclusion Criteria:

* history of asthma
* peptic ulcer
* severe hepatic or renal dysfunction
* neuropathies
* bleeding disorders
* uncooperative
* drug abuse
* sensibility to etoricoxib
* paracetamol or morphine
* long acting nonsteroidal antiinflammatory drugs (NSAID) in the last 4 days preoperative
* cerebrovascular and peripheric vascular disease
* arterial hypertension (HTA) not adequately controlled
* congestive heart failure.
D: Inclusion Criteria:

* Scheduled for unilateral, primary Total Hip Arthroplasty (THA)
* Age \> 18
* ASA 1-3.
* BMI \> 18 and \< 40
* Women in the fertile age must have negative urine HCG pregnancy test
* Patients who gave their written informed consent to participating in the trial after having fully understood the contents of the protocol and restrictions.

Exclusion Criteria:

* Patients who cannot cooperate with the trial.
* Concomitant participation in another trial
* Patients who cannot understand or speak Danish.
* Daily use of strong opioids (tramadol and codein are accepted)
* Patients with allergy to the medicines used in the trial.
* Contraindications against NSAID, for example previous ulcer, heart failure, liver failure, or renal failure (eGRF \< 60 ml/kg/1,73m2), known thrombocytopenia (\<100 mia/L)
* Patients suffering from alcohol and/or drug abuse - based on the investigator's judgement.

Answer: D